Cargando…
Prolactin and total lactogenic hormone measured by microbioassay and immunoassay in breast cancer.
Basal prolactin (PRL) and total lactogenic hormone (TLH) levels were measured using a new microbioassay (BA) and conventional immunoradiometric assay (IRMA) in patients with breast cancer and compared to an age-matched control group. No significant differences were found using the IRMA, but BA lacto...
Autores principales: | , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1992
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1977614/ https://www.ncbi.nlm.nih.gov/pubmed/1558804 |
_version_ | 1782135299591110656 |
---|---|
author | Maddox, P. R. Jones, D. L. Mansel, R. E. |
author_facet | Maddox, P. R. Jones, D. L. Mansel, R. E. |
author_sort | Maddox, P. R. |
collection | PubMed |
description | Basal prolactin (PRL) and total lactogenic hormone (TLH) levels were measured using a new microbioassay (BA) and conventional immunoradiometric assay (IRMA) in patients with breast cancer and compared to an age-matched control group. No significant differences were found using the IRMA, but BA lactogenic levels were significantly elevated in breast cancer patients compared controls, leading to a markedly elevated BA/IRMA ratio for both PRL (2.7 vs 1.4, P less than 0.0001) and TLH (2.8 vs 1.4, P less than 0.0001) which was greatest for postmenopausal women. Using the mean +2 standard deviations as the upper limit of normal, there was no significant difference between breast cancer patients and controls for IRMA, but BA and BA/IRMA PRL levels were elevated in 42% and 61% of the patients, respectively. There was a weak negative correlation of BA and IRMA PRL with age for normals (r = -0.53 for both) but no correlation was evident for breast cancer patients (r = 0.06 and -0.13, respectively) implying a sustained absolute and relative bioactive hyperprolactinaemia at all ages. These results show increased lactogenic bioactivity in breast cancer and suggest that different forms of bioactive prolactin undetected by IRMA (or enhancing serum factors) are present in the sera of these patients. |
format | Text |
id | pubmed-1977614 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 1992 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-19776142009-09-10 Prolactin and total lactogenic hormone measured by microbioassay and immunoassay in breast cancer. Maddox, P. R. Jones, D. L. Mansel, R. E. Br J Cancer Research Article Basal prolactin (PRL) and total lactogenic hormone (TLH) levels were measured using a new microbioassay (BA) and conventional immunoradiometric assay (IRMA) in patients with breast cancer and compared to an age-matched control group. No significant differences were found using the IRMA, but BA lactogenic levels were significantly elevated in breast cancer patients compared controls, leading to a markedly elevated BA/IRMA ratio for both PRL (2.7 vs 1.4, P less than 0.0001) and TLH (2.8 vs 1.4, P less than 0.0001) which was greatest for postmenopausal women. Using the mean +2 standard deviations as the upper limit of normal, there was no significant difference between breast cancer patients and controls for IRMA, but BA and BA/IRMA PRL levels were elevated in 42% and 61% of the patients, respectively. There was a weak negative correlation of BA and IRMA PRL with age for normals (r = -0.53 for both) but no correlation was evident for breast cancer patients (r = 0.06 and -0.13, respectively) implying a sustained absolute and relative bioactive hyperprolactinaemia at all ages. These results show increased lactogenic bioactivity in breast cancer and suggest that different forms of bioactive prolactin undetected by IRMA (or enhancing serum factors) are present in the sera of these patients. Nature Publishing Group 1992-03 /pmc/articles/PMC1977614/ /pubmed/1558804 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Research Article Maddox, P. R. Jones, D. L. Mansel, R. E. Prolactin and total lactogenic hormone measured by microbioassay and immunoassay in breast cancer. |
title | Prolactin and total lactogenic hormone measured by microbioassay and immunoassay in breast cancer. |
title_full | Prolactin and total lactogenic hormone measured by microbioassay and immunoassay in breast cancer. |
title_fullStr | Prolactin and total lactogenic hormone measured by microbioassay and immunoassay in breast cancer. |
title_full_unstemmed | Prolactin and total lactogenic hormone measured by microbioassay and immunoassay in breast cancer. |
title_short | Prolactin and total lactogenic hormone measured by microbioassay and immunoassay in breast cancer. |
title_sort | prolactin and total lactogenic hormone measured by microbioassay and immunoassay in breast cancer. |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1977614/ https://www.ncbi.nlm.nih.gov/pubmed/1558804 |
work_keys_str_mv | AT maddoxpr prolactinandtotallactogenichormonemeasuredbymicrobioassayandimmunoassayinbreastcancer AT jonesdl prolactinandtotallactogenichormonemeasuredbymicrobioassayandimmunoassayinbreastcancer AT manselre prolactinandtotallactogenichormonemeasuredbymicrobioassayandimmunoassayinbreastcancer |